Oppenheimer Reiterates “Buy” Rating for Recro Pharma (REPH)

Recro Pharma (NASDAQ:REPH)‘s stock had its “buy” rating restated by equities research analysts at Oppenheimer in a note issued to investors on Thursday.

Several other brokerages also recently issued reports on REPH. Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, March 21st. ValuEngine raised Recro Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. CIBC assumed coverage on Recro Pharma in a research note on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, UBS assumed coverage on Recro Pharma in a research note on Tuesday, February 13th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Recro Pharma has an average rating of “Buy” and an average target price of $14.21.

How to Become a New Pot Stock Millionaire

Shares of Recro Pharma stock opened at $10.58 on Thursday. The stock has a market capitalization of $213.51, a P/E ratio of -5.32 and a beta of -0.74. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.75 and a quick ratio of 1.55. Recro Pharma has a 1 year low of $5.81 and a 1 year high of $12.23.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.22. The firm had revenue of $19.04 million during the quarter, compared to the consensus estimate of $12.88 million. Recro Pharma had a negative return on equity of 75.97% and a negative net margin of 69.61%. research analysts forecast that Recro Pharma will post -3.02 earnings per share for the current year.

In other news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total transaction of $2,014,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Recro Pharma by 42.5% during the 3rd quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock worth $220,000 after purchasing an additional 7,308 shares in the last quarter. JT Stratford LLC raised its stake in shares of Recro Pharma by 7.8% during the 4th quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock worth $1,038,000 after purchasing an additional 8,120 shares in the last quarter. Cadence Capital Management LLC raised its stake in shares of Recro Pharma by 7.8% during the 4th quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after purchasing an additional 13,078 shares in the last quarter. BlackRock Inc. raised its stake in shares of Recro Pharma by 1.4% during the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after purchasing an additional 13,799 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Recro Pharma by 183.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 14,098 shares in the last quarter. 57.85% of the stock is owned by institutional investors.

WARNING: “Oppenheimer Reiterates “Buy” Rating for Recro Pharma (REPH)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3334561/oppenheimer-reiterates-buy-rating-for-recro-pharma-reph.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cognizant Technology Solutions  Earning Somewhat Favorable Press Coverage, Analysis Finds
Cognizant Technology Solutions Earning Somewhat Favorable Press Coverage, Analysis Finds
Ideal Power  Expected to Announce Quarterly Sales of $390,000.00
Ideal Power Expected to Announce Quarterly Sales of $390,000.00
$14.65 Million in Sales Expected for BankFinancial  This Quarter
$14.65 Million in Sales Expected for BankFinancial This Quarter
SilverBow Resources  Expected to Announce Quarterly Sales of $52.23 Million
SilverBow Resources Expected to Announce Quarterly Sales of $52.23 Million
$1.47 Earnings Per Share Expected for ONE Gas  This Quarter
$1.47 Earnings Per Share Expected for ONE Gas This Quarter
-$0.30 Earnings Per Share Expected for Dicerna Pharmaceuticals  This Quarter
-$0.30 Earnings Per Share Expected for Dicerna Pharmaceuticals This Quarter


© 2006-2018 Ticker Report. Google+.